Lamivudine 150mg tabs/PAC-60

Lamivudine 150mg film coated tablets, bottle or blister pack of 60
Indicative Price : Upon Request

NOTE: The description below is for a standard product. It is not specific to patent status and pricing policies that may apply at country level. This information is available on request from Supply Division: Contact: supply@unicef.org

General Description:
Lamivudine 150mg film coated tablets, pack of 60

Technical Specifications:
Each film coated scored tablet contains 150mg of Lamivudine
Tablets should be scored with at least one break line to allow for division of tablets into two parts, each containing the same amount of active ingredients.

Therapeutic class:
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI)

Standard shelf life:
36 Months

Other available formulations:
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.

Guidelines for use:
For more details, please click the links listed below:

WHO treatment guidelines


WHO Essential Medicines Library

or your regional national guidelines

For details about paediatric dosage schemes, please click the links listed below:


WHO Generic tool for assessing paediatric ARV dosing

Management of HIV infection in combination with at least two other antiretroviral drugs. By mouth (oral) PO.
Prevention of mother to child transmission (PMTCT): In combination with other drugs in the therapy for prevention of maternal-fetal transmission of HIV.

Packaging and storage:
Do not store above 30ºC (86ºF). Store in a tightly closed container. Do not freeze.
Keep out of reach and sight of children.
Keep in original pack.

Dispensing instructions:
Dispense in original container. Do not repack

Regulatory Status
For latest updates, please click the links listed below:

List of WHO Prequalified Medicines

List of USFDA approved and tentatively approved items

Further information
Component of a kit
(S1400097) is a component of S9901003- IEHK 2011 PEP Kit
Related Products